Breaking Finance News

Spectrum Pharmaceuticals Terminates Phase 3 Study- Shares Volatile

Shares of Spectrum Pharmaceuticals are volatile on high volume as news broke that it terminated a Phase 3 trial.

According to the filing, the title of the study is, “An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy”

It goes on to report, “The purpose of this study is to evaluate the effect of consolidation treatment Zevalin® versus maintenance treatment with Rituxan® on progression-free survival (PFS) following response induction with chemotherapy plus rituximab in previously untreated patients with follicular lymphoma.”

Zevalin is already approved for the treatment of lymphoma patients. It contains two treatments of rituximab and one treatment of Yttrium-90.

[stock-tools exchange="NASDAQ" symbol="SPPI" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.